- Investing Ideas
- /
- Swedish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Swedish Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
5
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
5 companies
Bonesupport Holding
Market Cap: SEK 21.3b
An orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.
BONEX
SEK 323.20
7D
-3.6%
1Y
22.1%
Vitrolife
Market Cap: SEK 18.9b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
VITR
SEK 139.20
7D
-2.9%
1Y
-36.6%
BioGaia
Market Cap: SEK 9.6b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 95.30
7D
-3.0%
1Y
-21.8%
Genovis AB (publ.)
Market Cap: SEK 1.7b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 26.00
7D
-6.3%
1Y
-9.4%
Double Bond Pharmaceutical International
Market Cap: SEK 12.9m
A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases.
DBP B
SEK 0.12
7D
9.1%
1Y
-72.7%